
Claims

1. A compound of Formula (II')



(II')

and/or its stereoisomers or tautomers, or pharmaceutically acceptable salts of each of the foregoing, including mixtures thereof in all ratios, wherein:

R^1, R^2 are H,

$R^{3'}$, $R^{3''}$ independently are H, LA or Hal,

R^4, R^5, R^6, R^7, R^8, independently are H, Hal, LA, OH, SH, O(LA), NH_2, NH(LA), $N(LA)_2$, NO_2, CN, OCN, SCN, COOH, COO(LA), $CONH_2$, CONH(LA), $CON(LA)_2$, NHCO(LA), NHCONH(LA), $NHCONH_2$, $NHSO_2$(LA), CO(LA), SO_2NH_2, SO_2(LA) or SO_2Hal,

R^5, R^6 together with the phenyl group they are attached to, may form a 9 or 10 membered bicyclic ring system, in which 1 or 2 of the non-phenyl carbon atoms may be independently replaced by NH, O or S, in which the cycle formed by R^5 and R^6 may be unsubstituted or mono- or disubstituted by Hal or LA,

One of R^5, R^6, R^7

may be Ar1, O(Ar1), NH(Ar1), CONH(Ar1), NHCO(Ar1), NHCONH(Ar1), $NHSO_2$(Ar1), CO(Ar1) or SO_2(Ar1),

while the other two of R^5, R^6, R^7 are not Ar1, O(Ar1), NH(Ar1), CONH(Ar1), NHCO(Ar1), NHCONH(Ar1), $NHSO_2$(Ar1), CO(Ar1) or SO_2(Ar1),

Ar1 is a monocyclic aromatic homo- or heterocycle having 0, 1, 2 or 3 N, O and/or S atoms and 5 or 6 skeleton atoms, which may be unsubstituted or, independently of one another, mono-, di- or trisubstituted by Hal, LA, OH, SH, O(LA), NH_2, NH(LA), $N(LA)_2$, NO_2, CN, OCN, SCN, COOH, COO(LA), $CONH_2$, CONH(LA), $CON(LA)_2$, NHCO(LA), CHO, CO(LA), SO_2NH_2, SO_2(LA) and/or SO_2Hal,

LA is unbranched or branched, linear alkyl having 1, 2, 3 or 4 C atoms, wherein 1, 2 or 3 H atoms may be replaced by Hal, and

Hal is F, Cl or Br.

2. The compound according to Claim 1, which conforms to Formula (II'), or its stereoisomers or tautomers, or pharmaceutically acceptable salts of each of the foregoing, including mixtures thereof in all ratios, in which the residues not designated in greater detail have the meaning indicated for Formula (II'), but in which

in Subformula 1

R^4, R^5, R^6, R^7, R^8 independently are H, F, Cl, Br, OH, LA, O(LA), CN, $C(Hal)_3$, $OC(Hal)_3$,

in Subformula 2

$R^{3'}$, $R^{3''}$ independently are H or F,

in Subformula 3

R^4, R^8 independently are H, F or Cl,

in Subformula 4

R^5, R^7 independently are H, F, Cl, Br, CN, methoxy or CF_3,

in Subformula 5

R^5, R^6 together with the phenyl group they are attached to, form benzo-1,2-dioxolyl, of which the carbon atom bridging the two oxygen atoms may be unsubstituted, or mono- or disubstituted by F or methyl,

in Subformula 6

R^6 is H, F, Cl or CF_3,

in Subformula 7

R^5, R^6 independently are H, F, Cl, Br, methyl, CHF_2 or CF_3,

in Subformula 8

R^1, R^2, $R^{3'}$, $R^{3''}$, R^4, R^7, R^8 are H,

in Subformula 9

R^1, R^2, $R^{3'}$, $R^{3''}$, R^4, R^7, R^8 are H,

R^5, R^6 are independently H, F, Cl, Br, methyl, CHF_2 or CF_3,

in Subformula 10

R^1, R^2, $R^{3'}$, $R^{3''}$, R^4, R^8 are H,

R^5 is Br, methyl, CHF_2 or CF_3,

R^6 is F, Cl or CF_3,

R^7 is H or F,

in Subformula 11

R^1, R^2, R^4, R^8 are H,

$R^{3'}$ is F, or methyl,

$R^{3''}$ is H,

R^5 is Br, methyl, CHF_2 or CF_3,

R^6 is F, Cl or CF_3,

R^7 is H or F,

3. The compound according to Claim 1, wherein the compound is selected from the group consisting of:

4-[(S)-2-Azetidin-1-yl-1-(3-fluorophenyl)-ethylamino]-quinazoline-8-carboxylic acid amide;

4-[(S)-2-Azetidin-1-yl-1-(3-chlorophenyl)-ethylamino]-quinazoline-8-carboxylic acid amide;

4-[(S)-2-Azetidin-1-yl-1-(4-fluorophenyl)-ethylamino]-quinazoline-8-carboxylic acid amide;

4-[(S)-2-Azetidin-1-yl-1-(3,4-difluorophenyl)-ethylamino]-quinazoline-8-carboxylic acid amide;

4-[(S)-2-Azetidin-1-yl-1-(4-chloro-3-trifluoromethylphenyl)-ethylamino]-quinazoline-8-carboxylic acid amide;

4-[(S)-2-Azetidin-1-yl-1-(3-fluoro-5-trifluoromethylphenyl)-ethylamino]-quinazoline-8-carboxylic acid amide;

4-[(S)-2-Azetidin-1-yl-1-(3-chloro-4-fluorophenyl)-ethylamino]-quinazoline-8-carboxylic acid amide;

4-[(S)-2-Azetidin-1-yl-1-(4-bromophenyl)-ethylamino]-quinazoline-8-carboxylic acid amide;

4-[(S)-2-Azetidin-1-yl-1-(4-trifluoromethylphenyl)-ethylamino]-quinazoline-8-carboxylic acid amide;

4-[(S)-2-Azetidin-1-yl-1-(4-chlorophenyl)-ethylamino]-quinazoline-8-carboxylic acid amide;

4-[(S)-2-Azetidin-1-yl-1-(3-cyanophenyl)-ethylamino]-quinazoline-8-carboxylic acid amide;

4-[(S)-2-Azetidin-1-yl-1-(3-methoxyphenyl)-ethylamino]-quinazoline-8-carboxylic acid amide;

4-[(S)-2-Azetidin-1-yl-1-(3-bromophenyl)-ethylamino]-quinazoline-8-carboxylic acid amide;

4-[(S)-2-Azetidin-1-yl-1-(2-fluoro-4-chlorophenyl)-ethylamino]-quinazoline-8-carboxylic acid amide;

4-[(S)-2-Azetidin-1-yl-1-(2,4-difluorophenyl)-ethylamino]-quinazoline-8-carboxylic acid amide;

4-[(S)-2-Azetidin-1-yl-1-(2,6-difluorophenyl)-ethylamino]-quinazoline-8-carboxylic acid amide;

4-[(S)-2-Azetidin-1-yl-1-(3-chloro-4-trifluoromethylphenyl)-ethylamino]-quinazoline-8-carboxylic acid amide;

4-[(S)-2-Azetidin-1-yl-1-(2,4,5-trifluorophenyl)-ethylamino]-quinazoline-8-carboxylic acid amide;

4-[(S)-2-Azetidin-1-yl-1-(2,3,4-trifluorophenyl)-ethylamino]-quinazoline-8-carboxylic acid amide;

4-[(S)-2-Azetidin-1-yl-1-(1-benzo[1,3]dioxol)-ethylamino]-quinazoline-8-carboxylic acid amide;

4-[(S)-2-Azetidin-1-yl-1-phenyl-ethylamino]-quinazoline-8-carboxylic acid amide;

4-[(S)-2-(3-Fluoro-azetidin-1-yl)-1-(3-chlorophenyl)-ethylamino]-quinazoline-8-carboxylic acid amide;

4-[(S)-2-Azetidin-1-yl-1-(4-cyano-phenyl)-ethylamino]-quinazoline-8-carboxylic acid amide;

4-[(S)-2-Azetidin-1-yl-1-(2-chloro-4-fluoro-phenyl)-ethylamino]-quinazoline-8-carboxylic acid amide;

4-[(S)-2-Azetidin-1-yl-1-(2-chloro-5-fluoro-phenyl)-ethylamino]-quinazoline-8-carboxylic acid amide;

4-[(S)-2-Azetidin-1-yl-1-(2,5-di-fluoro-phenyl)-ethylamino]-quinazoline-8-carboxylic acid amide;

4-[(S)-2-Azetidin-1-yl-1-(3-trifluoromethyl-phenyl)-ethylamino]-quinazoline-8-carboxylic acid amide;

4-[(S)-2-Azetidin-1-yl-1-(3-chloro-4-trifluoromethoxy-phenyl)-ethylamino]-quinazoline-8-carboxylic acid amide;

4-[(S)-2-Azetidin-1-yl-1-(4-chloro-3-fluoro-phenyl)-ethylamino]-quinazoline-8-carboxylic acid amide;

4-[(S)-2-Azetidin-1-yl-1-(4-trifluoromethoxy-phenyl)-ethylamino]-quinazoline-8-carboxylic acid amide;

4-[(S)-2-Azetidin-1-yl-1-(4-fluoro-3-trifluoromethyl-phenyl)-ethylamino]-quinazoline-8-carboxylic acid amide;

4-[(S)-1-(4-Chloro-phenyl)-2-(3,3-difluoro-azetidin-1-yl)-ethylamino]-quinazoline-8-carboxylic acid amide;

4-[(S)-2-Azetidin-1-yl-1-(4-isopropylphenyl)-ethylamino]-quinazoline-8-carboxylic acid amide;

4-[(S)-2-Azetidin-1-yl-1-(4-carbamoylphenyl)-ethylamino]-quinazoline-8-carboxylic acid amide;

4-[(S)-2-Azetidin-1-yl-1-(4-isopropoxyphenyl)-ethylamino]-quinazoline-8-carboxylic acid amide;

4-[(S)-2-Azetidin-1-yl-1-(3,4,5-trifluorophenyl)-ethylamino]-quinazoline-8-carboxylic acid amide;

4-[(S)-2-Azetidin-1-yl-1-(3,5-difluoro-4-methoxyphenyl)-ethylamino]-quinazoline-8-carboxylic acid amide;

4-[(S)-2-Azetidin-1-yl-1-(3-cyano-4-fluorophenyl)-ethylamino]-quinazoline-8-carboxylic acid amide;

4-[(S)-2-Azetidin-1-yl-1-(3,4-difluoro-5-methoxyphenyl)-ethylamino]-quinazoline-8-carboxylic acid amide;

4-[(S)-2-Azetidin-1-yl-1-(3-fluoro-4,5-dichlorophenyl)-ethylamino]-quinazoline-8-carboxylic acid amide;

4-[(S)-2-Azetidin-1-yl-1-(4-fluoro-3-methyl-phenyl)-ethylamino]-quinazoline-8-carboxylic acid amide;
4-[(S)-2-Azetidin-1-yl-1-(4-fluoro-3-methoxy-phenyl)-ethylamino]-quinazoline-8-carboxylic acid amide;
4-[(S)-2-Azetidin-1-yl-1-(3-difluoromethyl-4-fluoro-phenyl)-ethylamino]-quinazoline-8-carboxylic acid amide;
4-[(S)-1-(4-Fluoro-3-trifluoromethyl-phenyl)-2-(3-methyl-azetidin-1-yl)-ethylamino]-quinazoline-8-carboxylic acid amide;
4-[(S)-1-(4-Fluoro-3-trifluoromethyl-phenyl)-2-(2-methyl-azetidin-1-yl)-ethylamino]-quinazoline-8-carboxylic acid amide;
4-[(S)-2-(3-Fluoro-azetidin-1-yl)-1-(4-fluoro-3-trifluoromethyl-phenyl)-ethylamino]-quinazoline-8-carboxylic acid amide;
4-[(S)-2-Azetidin-1-yl-1-(3-cyano-4-fluoro-phenyl)-ethylamino]-quinazoline-8-carboxylic acid amide;
4-[(S)-2-Azetidin-1-yl-1-(4-benzoylamino-phenyl)-ethylamino]-quinazoline-8-carboxylic acid amide;
4-[(S)-2-(3-Fluoro-azetidin-1-yl)-1-(4-chloro-3-trifluoromethyl-phenyl)-ethylamino]-quinazoline-8-carboxylic acid amide;
and/or its stereoisomers or tautomers, or pharmaceutically acceptable salts of each of the foregoing, including mixtures thereof in all ratios.

4. A pharmaceutical composition comprising a compound according to any of claims 1 to 3, and/or its stereoisomers or tautomers, or pharmaceutically acceptable salts of each of the foregoing, including mixtures thereof in all ratios, as active ingredient, together with a pharmaceutically acceptable carrier.

5. A compound of any of claims 1 to 3, and/or its stereoisomers or tautomers, or pharmaceutically acceptable salts of each of the foregoing, including mixtures thereof in all ratios, for use as a medicament.

6. A compound of any of claims 1 to 3, and/or its stereoisomers or tautomers, or pharmaceutically acceptable salts of each of the foregoing, including mixtures thereof in all ratios, for treating hyperproliferative diseases.

7. The compound for use according to of claim 6, and/or its stereoisomers or tautomers, or pharmaceutically acceptable salts of each of the foregoing, including mixtures thereof in all ratios, wherein the hyperproliferative disease is cancer.

8. The compound for use according to of claim 7, and/or its stereoisomers or tautomers, or pharmaceutically acceptable salts of each of the foregoing, including mixtures thereof in all ratios, wherein the cancer is selected from a group consisting of brain, lung, colon, epidermoid, squamous cell, bladder, gastric, pancreatic, breast, head, neck, renal, kidney, liver, ovarian, prostate, colorectal, uterine, rectal, oesophageal, testicular, gynecological, or thyroid cancer, or melanoma, hematologic malignancies such as acute myelogenous leukemia, multiple myeloma, chronic myelogneous leukemia, myeloid cell leukemia, glioma, Kaposi's sarcoma.

9. Use of a compound of any of claims 1 to 3, or and/or its stereoisomers or tautomers, or pharmaceutically acceptable salts of each of the foregoing, including mixtures thereof in all ratios, for the preparation of a medicament for the treatment of hyperproliferative diseases.

10. Use according to claim 9 wherein the hyperproliferative disease is cancer.

11. Use according to claim 10 wherein the cancer is selected from a group consisting of brain, lung, colon, epidermoid, squamous cell, bladder, gastric, pancreatic, breast, head, neck, renal, kidney, liver, ovarian, prostate, colorectal, uterine, rectal, oesophageal, testicular, gynecological, or thyroid cancer, or melanoma, hematologic malignancies such as acute myelogenous leukemia, multiple myeloma, chronic myelogneous leukemia, myeloid cell leukemia, glioma, Kaposi's sarcoma.


12. Set (kit) consisting of separate packs of

a) an effective amount of a compound according to any of Claims 1 to 3 and/or its stereoisomers or tautomers, or pharmaceutically acceptable salts of each of the foregoing, including mixtures thereof in all ratios, and

b) an effective amount of a further medicament active ingredient.


13. Process for the manufacture of compounds of Formula (II'), wherein LG is a leaving group, and the remaining substituents have the meaning as defined for Formula (II') in Claim 1,

wherein a compound of Formula (V)




(V),

is reacted with a compound of Formula (IV)



(IV),

to yield a carboxylic ester compound of Formula (III),



(III),

which is then converted to a carboxamide compound of Formula (II').